Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 1998

View Archived Issues

DNA immunization against rabies effectively protects nonhuman primates

Alpha-Beta Technology: Q2 1998 highlights

Orion: six-month highlights

Late-stage clinical trials of Oralin to begin in Canada

Canadian launch for minimally invasive impotence treatment

Phase II trial commences of AG-3340 in AMD

Inhibitors of telomerase focus of investigation at CRC Technology, U. Texas

Japanese and Dutch scientists design LTD4 and dual LTD4/H1 antagonists

Amersham Pharmacia Biotech completes tender offer for Molecular Dynamics

Selective 5-HT2C antagonist selected for development at Organon

SuperGen expands phase III trials of RFS-2000 in pancreatic cancer

Russian scientists identify GABA analogue with hypotensive activity

Astra Arcus develops first full, selective alpha7 nAChR agonist

Glaxo Wellcome studies lamotrigine analogues in the search for new anticonvulsants

Organon discovers new pharmacophore providing potent, orally active thrombin inhibitors

Novo files for U.S. marketing approval of insulin analogue

First group 1 mGluR antagonist with submicromolar potency described by Lilly

GW-273227, a sodium channel blocker for the treatment of pain

Advisory committee unanimously recommends approval for Enbrel

Nasal calcitonin reduces spinal fractures in postmenopausal women with osteoporosis

Medical device for rheumatoid arthritis scheduled for October advisory panel review

New treatment for BPH discovered by Hungarian research team

Famciclovir effectively suppresses recurrent genital herpes

Baxter refocuses blood substitute program

IND filed for new insomnia drug candidate from Neurogen and Pfizer

Neurogen epilepsy drug candidate undergoes further preclinical trials

La Jolla identifies target of antibodies responsible for life-threatening autoimmune disorder

Sanofi/BMS antiplatelet agent introduced in U.K.

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...